| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b72691b61448140b9a080282c2ccf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74935159a0a871dd85e00c138f7fe6b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1214ea6126e22201719e33429b05e79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880fdc5c9e462accc3295cd34e46f393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39ca42a0f3eeba4621a7369292a02323 |
| publicationDate |
2020-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200045666-A |
| titleOfInvention |
Composition for preventing or treating non small cell lung cancer harboring the EGFR mutations |
| abstract |
The present invention relates to a composition for preventing, improving or treating EGFR-mutated non-small cell lung cancer, which includes a JNK (c-Jun N-terminal kinase) activator as an active ingredient. The composition for preventing, improving or treating EGFR-mutated non-small cell lung cancer of the present invention is useful for the prevention, improvement or treatment of non-small cell lung cancer by significantly reducing the EGFR level of EGFR-mutated non-small cell lung cancer cells to induce apoptosis. Can be used. In particular, it is possible to effectively treat and prevent non-small cell lung cancer that gefitinib or erlotinib does not work. In addition, the composition for inhibiting resistance of non-small cell lung cancer to an EGFR tyrosine kinase inhibitor of the present invention effectively overcomes resistance to an EGFR tyrosine kinase inhibitor. |
| priorityDate |
2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |